Carlos Aguiar

Ventral cardiac denervation reduces the incidence of atrial fibrillation after coronary artery bypass grafting

OBJECTIVES Because the autonomic nervous system is an important determinant in the appearance of atrial fibrillation, we have assessed the role of ventral cardiac denervation for its prevention. METHODS Patients undergoing low-risk coronary artery surgery were enrolled. No routine antiarrhythmic drugs were administered before or after the operation. Ventral cardiac denervation was performed in 207 patients, and 219 patients were used as control subjects. Denervation was performed before cardiopulmonary bypass. The groups were comparable regarding demographic, clinical, and operative variables. RESULTS The additional time for the denervation was 5 +/- 2 minutes, and there were no associated complications. Postoperative atrial fibrillation was present in 15 (7%) patients undergoing ventral cardiac denervation (95% confidence interval, 4%-12%) and in 56 (27%) control subjects (95% confidence interval, 18%-35%). Patients submitted to ventral cardiac denervation had fewer and less severe episodes of atrial fibrillation, and no patient had atrial fibrillation after discharge. Ventral cardiac denervation was the most significant predictor of postoperative atrial fibrillation (odds ratio, 0.42; confidence interval, 0.23-0.78; P =.006). Age of greater than 65 years (odds ratio, 1.67; confidence interval, 0.96-2.9; P =.067) was a highly suggestive predictor. The analysis of the effect of ventral cardiac denervation correlated with the patients age showed a more pronounced effect in patients younger than 70 years (odds ratio, 0.43; confidence interval, 0.22-0.86; P =.022) CONCLUSIONS Ventral cardiac denervation is a fast and low-risk procedure. Its use significantly reduces the incidence and severity of atrial fibrillation after routine coronary artery bypass surgery. Patients younger than 70 years of age are expected to have a higher success rate than those older than 70 years.

Subacute left ventricle free wall rupture after acute myocardial infarction: awareness of the clinical signs and early use of echocardiography may be life-saving

Left ventricular free wall rupture (LVFWR) is a fearful complication of acute myocardial infarction in which a swift diagnosis and emergency surgery can be crucial for successful treatment. Because a significant number of cases occur subacutely, clinicians should be aware of the risk factors, clinical features and diagnostic criteria of this complication. We report the case of a 69 year-old man in whom a subacute left ventricular free wall rupture (LVFWR) was diagnosed 7 days after an inferior myocardial infarction with late reperfusion therapy. An asymptomatic 3 to 5 mm saddle-shaped ST-segment elevation in anterior and lateral leads, detected on a routine ECG, led to an urgent bedside echocardiogram which showed basal inferior-wall akinesis, a small echodense pericardial effusion and a canalicular tract from endo to pericardium, along the interface between the necrotic and normal contracting myocardium, trough which power-Doppler examination suggested blood crossing the myocardial wall. A cardiac MRI further reinforced the possibility of contained LVFWR and a surgical procedure was undertaken, confirming the diagnosis and allowing the successful repair of the myocardial tear. This case illustrates that subacute LVFWR provides an opportunity for intervention. Recognition of the diversity of presentation and prompt use of echocardiography may be life-saving.

Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years

AIMS Redefinition of myocardial infarction (MI) based on specific cardiac troponins (cTn) was universally accepted in 2007. The new definition has been widely discussed for including a large spectrum of quantitative myocardial necrosis and their clinical implications remain under debate. Our aim was to assess the impact of the universal definition of MI on mortality at 10 years. METHODS AND RESULTS We studied 676 consecutive patients (Pts) admitted to our intensive cardiac care unit for acute coronary syndrome (ACS) between January 1999 and December 2000. We calculated the relative risk of the total death at 10 years adjusted with the Cox proportional hazards model, between the presence and absence of MI following different definitions: (1), typical symptoms and persistent ST-segment elevation or left bundle branch block (ST-segment elevation definition); (2), typical symptoms and CK-MB activity rise and/or fall >ULN (old definition); and (3), typical symptoms and cTn I rise and/or fall >99th percentile (universal definition). The total mortality at 10 years was 23.8%. The proportion of Pts with AMI was 33.6% for ST-segment elevation definition, 55.8% for old definition, and 70.1% for universal definition. The adjusted hazard ratio of death at 10 years between the presence and absence of AMI was 0.71 (95% confidence interval (CI): 0.46-1.08; P = 0.11) for ST-segment elevation definition, 0.84 (95% CI: 0.55-1.27; P = 0.40) for old definition, and 1.58 (95% CI: 1.07-2.40; P = 0.03) for universal definition. Patients submitted to myocardial revascularization during the initial hospital stay (72%) presented a significantly lower mortality at 10 years, compared with patients not revascularized (adjusted hazard ratio: 0.63, 95% CI: 0.44-0.91; P = 0.014). CONCLUSIONS In a population with the entire spectrum of ACSs, the universal definition of MI increased this diagnosis by one-quarter and was an independent predictor of mortality at 10 years. Furthermore, myocardial revascularization was associated with a significantly lower mortality at 10 years.

Prognosis in patients with left bundle branch block and normal dipyridamole thallium-201 scintigraphy

BackgroundThe presence of complete left bundle branch block (LBBB) is commonly associated with a poorer prognosis, especially in patients with coronary artery disease (CAD). In the general population with suspected CAD and normal intraventricular conduction, a normal dipyridamole-thallium scintigraphy is a strong marker of a favorable outcome.ObjectiveOur objective was to assess the prognosis in patients with LBBB and a normal dipyridamole thallium-201 scintigram.Population and methodsPatients with complete LBBB and normal myocardial perfusion on dipyridamole SPECT thallium-201 scintigraphy performed in our center for suspected CAD between 1988 and 1995 were monitored for clinical events.ResultsSixty-nine patients (36 women and 33 men) with a mean age of 59 years (range 56 to 61) were monitored for a mean period of 33 months (range 25 to 35). During this period, 4 patients had unstable angina, 2 of whom underwent myocardial revascularization. There were no deaths or myocardial infarction. All events occurred at least 2 years after the thallium-201 scintigraphy.ConclusionThe presence of a normal myocardial perfusion with dipyridamole thallium-201 scintigraphy in this group of patients with suspected CAD and LBBB was associated with a very good prognosis, a low rate of clinical events occurring only 2 years after the myocardial scintigraphy, and no hard events.

Mitral annular disjunction in myxomatous mitral valve disease: a relevant abnormality recognizable by transthoracic echocardiography

BackgroundMitral annular disjunction (MAD) consists of an altered spatial relation between the left atrial wall, the attachment of the mitral leaflets, and the top of the left ventricular (LV) free wall, manifested as a wide separation between the atrial wall-mitral valve junction and the top of the LV free wall. Originally described in association with myxomatous mitral valve disease, this abnormality was recently revisited by a surgical group that pointed its relevance for mitral valve reparability. The aims of this study were to investigate the echocardiographic prevalence of mitral annular disjunction in patients with myxomatous mitral valve disease, and to characterize the clinical profile and echocardiographic features of these patients.MethodsWe evaluated 38 patients with myxomatous mitral valve disease (mean age 57 ± 15 years; 18 females) and used standard transthoracic echocardiography for measuring the MAD. Mitral annular function, assessed by end-diastolic and end-systolic annular diameters, was compared between patients with and without MAD. We compared the incidence of arrhythmias in a subset of 21 patients studied with 24-hour Holter monitoring.ResultsMAD was present in 21 (55%) patients (mean length: 7.4 ± 8.7 mm), and was more common in women (61% vs 38% in men; p = 0.047). MAD patients more frequently presented chest pain (43% vs 12% in the absence of MAD; p = 0.07). Mitral annular function was significantly impaired in patients with MAD in whom the mitral annular diameter was paradoxically larger in systole than in diastole: the diastolic-to-systolic mitral annular diameter difference was -4,6 ± 4,7 mm in these patients vs 3,4 ± 1,1 mm in those without MAD (p < 0.001). The severity of MAD significantly correlated with the occurrence of non-sustained ventricular tachycardia (NSVT) on Holter monitoring: MAD›8.5 mm was a strong predictor for (NSVT), (area under ROC curve = 0.74 (95% CI, 0.5-0.9); sensitivity 67%, specificity 83%). There were no differences between groups regarding functional class, severity of mitral regurgitation, LV volumes, and LV systolic function.ConclusionsMAD is a common finding in myxomatous mitral valve disease patients, easily recognizable by transthoracic echocardiography. It is more prevalent in women and often associated with chest pain. MAD significantly disturbs mitral annular function and when severe predicts the occurrence of NSVT.

Aortic Coarctation Repair in the Adult

Aortic coarctation can be repaired surgically or percutaneously. The decision should be made according to the anatomy and location of the coarctation, age of the patient, presence of other cardiac lesions, and other anatomic determinants (extensive collaterals or aortic calcification). This article reviews the different therapeutic options available, explaining the differences between children and adults, describing different approaches to the same disease, exemplified by three cases of nonclassic surgical approach and one percutaneous treatment. doi: 10.1111/jocs.12367 (J Card Surg 2014;29:512–518)

Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia

A panel of European experts on lipids and cardiovascular disease discussed clinical approaches to managing cardiovascular risk in clinical practice, including residual cardiovascular risk associated with lipid abnormalities, such as atherogenic dyslipidaemia (AD). A simplified definition of AD was proposed to enhance understanding of this condition, its prevalence, and its impact on cardiovascular risk. Atherogenic dyslipidaemia can be defined by high fasting triglyceride levels (≥2.3 mmol/L) and low high-density lipoprotein cholesterol (HDL-c) levels (≤1.0 and ≤1.3 mmol/L in men and women, respectively) in statin-treated patients at high cardiovascular risk. The use of a single marker for the diagnosis and treatment of AD, such as non-HDL-c, was advocated. Interventions including lifestyle optimization and low-density lipoprotein (LDL)-lowering therapy with statins (±ezetimibe) are implemented by all experts. Treatment of residual AD can be performed with the addition of fenofibrate, since it can improve the complete lipoprotein profile and reduce the risk of cardiovascular events in patients with AD. Specific clinical scenarios in which fenofibrate may be prescribed are discussed, and include patients with very high triglycerides (≥5.6 mmol/L), patients who are intolerant or resistant to statins, and patients with AD and at high cardiovascular risk. The fenofibrate-statin combination was considered by the experts to benefit from a favourable benefit-risk profile. Cardiovascular experts adopt a multifaceted approach to the prevention of atherosclerotic cardiovascular disease, with lifestyle optimization, LDL-lowering therapy, and treatment of AD with fenofibrate routinely used to help reduce a patients overall cardiovascular risk.

Does continuous ST-segment monitoring add prognostic information to the TIMI, PURSUIT, and GRACE risk scores?

Background: Recurrent ischemia is frequent in patients with non‐ST‐elevation acute coronary syndromes (NST‐ACS), and portends a worse prognosis. Continuous ST‐segment monitoring (CSTM) reflects the dynamic nature of ischemia and allows the detection of silent episodes. The aim of this study is to investigate whether CSTM adds prognostic information to the risk scores (RS) currently used.

Prevenção do tromboembolismo na fibrilhação auricular

Resumo A fibrilhacao auricular (FA) e a arritmia cronica mais prevalente na populacao. O seu prognostico e marcado, sobretudo, pelos fenomenos tromboembolicos a que esta associada. Em cada seis acidentes vasculares cerebrais (AVC) isquemicos, um deve-se a FA, mas a proporcao de AVC isquemicos atribuiveis a FA aumenta em funcao da idade. A estratificacao do risco tromboembolico e um componente critico da avaliacao clinica do doente com FA, um indicador de qualidade dos cuidados de saude e serve para orientar a estrategia terapeutica antitrombotica. A anticoagulacao oral (ACO) com antivitaminicos K e eficaz na prevencao do AVC em doentes com FA nao valvular mas, por multiplos motivos, e largamente subutilizada no mundo real e muitas vezes os niveis da Razao Normalizada Internacional (RNI) ficam abaixo dos valores terapeuticos. Os novos farmacos ACO sao inibidores da trombina ou do factor Xa e sao de aplicacao mais facil, dispensando monitorizacao laboratorial. Em ensaios clinicos de fase III, estes farmacos mostraram ser pelo menos tao eficazes quanto a varfarina, mas mais seguros, particularmente em relacao ao risco de hemorragia intracraniana, complicacao que e responsavel por 90% das mortes atribuiveis a varfarina. Estes resultados permitem antever o potencial para aumentar a proporcao de doentes com FA adequadamente anticoagulados, o que representara um avanco significativo na prevencao do AVC atribuivel a FA.

Applicability of the Zwolle risk score for safe early discharge after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction.

INTRODUCTION AND AIM The optimal length of stay for patients with uncomplicated ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI) is still undetermined. The Zwolle risk score (ZRS) is a simple tool designed to identify patients who can be safely discharged within 72 hours. The purpose of this study was to assess the applicability and performance of the ZRS in our population. METHODS We studied 276 consecutive patients (mean age 62 ± 14 years, 75% male, 20% Killip class >1) admitted over a two-year period for STEMI and treated with PPCI. ZRS, length of stay, 30-day mortality and readmission were obtained for all patients. Low risk was defined as ZRS ≤ 3. RESULTS The median ZRS was 3 (interquartile range [IQR] 1-4), with 171 patients (62%) being classified as low risk. Thirty-day mortality was 4.7% (13 patients). Compared to other patients, low-risk patients had shorter length of stay (median 5.0 [IQR 4-7] vs. 7.0 [5-13] days, p<0.001), and lower 30-day mortality (0 vs. 12.4%, p<0.001), yielding a negative predictive value of 100% (95% CI 97.0-100%) for the proposed cutoff. The ZRS showed excellent discriminative power (C-statistic: 0.937, 95% CI 0.906-0.968, p<0.001), and good calibration against the original cohort. CONCLUSIONS The ZRS appears to perform well in identifying low-risk STEMI patients who could be safely discharged within 72 hours of admission. Using the ZRS in our population could result in a more rational use of in-patient resources.